MedTrace Logo

Cannabidiol for Treatment Resistant Depression

NCT04732169 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2021-07-19

No results posted yet for this study

Summary

With this study, the investigators will address the following scientific aims:

1. Demonstrate the antidepressant effects of CBD in human adults with treatment refractory MDD as measured by standard rating scales.
2. Confirm CBD's safety profile in human adult patients with MDD.

Conditions

Interventions

DRUG

Active study drug ( oral CBD)

CBD in single dose syringes

DRUG

matching placebo

Placebo made with sesame oil flavored with strawberry flavoring in single dose syringes

Sponsors & Collaborators

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • Matthew Macaluso, D.O. · University ot Alabama at Birmingham

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2021-07-09
Completion
2021-07-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04732169 on ClinicalTrials.gov